A dose-finding Phase I study of F8IL10 intra-articular treatment in Rheumatoid Arthritis
PH-F8IL10INTRA-03/24
Phase 1 other active
Quick answer
A dose-finding Phase I study of F8IL10 intra-articular treatment in Rheumatoid Arthritis for Patients with Rheumatoid Arthritis (RA) who, despite treatment with stable doses (for at least 3 months) of disease-modifying antirheumatic drugs (DMARDs, conventional, biologic and/or targeted synthetic), present arthritis flare(s) suitable for intra-articular (IA) injection in a knee, shoulder, ankle, wrist or elbow. is a Phase 1 program (other) at Philogen S.p.A. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Philogen S.p.A.
- Indication
- Patients with Rheumatoid Arthritis (RA) who, despite treatment with stable doses (for at least 3 months) of disease-modifying antirheumatic drugs (DMARDs, conventional, biologic and/or targeted synthetic), present arthritis flare(s) suitable for intra-articular (IA) injection in a knee, shoulder, ankle, wrist or elbow.
- Phase
- Phase 1
- Modality
- other
- Status
- active